|
KMID : 1144320210530040686
|
|
감염과 화학요법
2021 Volume.53 No. 4 p.686 ~ p.695
|
|
|
Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention
|
|
Kim Yeon-Sook
|
|
|
Abstract
|
|
|
|
Current oral antiretroviral agents provide highly effective treatment for patients infected with human immunodeficiency virus (HIV), and can be used as pre-exposure prophylaxis (PrEP) to prevent new HIV infections. Several single-tablet regimens with excellent antiviral efficacy have dramatically improved the quality of life of patients who can adhere to daily oral therapy. However, there is increasing demand on long-acting injectable antiretroviral agents for patients who cannot take oral agents or feel fatigue related to daily pill burden. Monthly long-acting (LA) cabotegravir (CAB) combined with rilpivirine (RPV) has recently been listed as optimizing agent for maintenance of HIV suppression in treatment-experienced patients whose viral load is undetectable for 3 to 6 months. Novel agents with different mechanism of action and long half-life extending dosing interval are being tested in phase 2 and 3 clinical trials. This review summarizes the data of efficacies and safety profiles of LA CAB with RPV regimen, and also new long-acting injectable antiretroviral agents in pipeline.
|
|
|
KEYWORD
|
|
|
Human immunodeficiency virus, Long-acting, Injectable antiretroviral agents, Pre-exposure prophylaxis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|